About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Found 1248 record(s)
Req # A-2020-001106
Adverse Reaction Reports (AERs) for FLUDARABINE PHOSPHATE. Report numbers: E2B_03157812, E2B_03154000, E2B_03185091.Organization: Health Canada
February 2021
Req # A-2020-001109
Adverse Reaction Reports (AERs) for HYDROXYCHLOROQUINE SULFATE. Report numbers: E2B_03079317, E2B_03076907, E2B_03075342, E2B_03066329, E2B_03161923.Organization: Health Canada
February 2021
Req # A-2020-001121
Adverse Reaction Reports (AERs) for CEFIXIME. Report numbers: E2B_03008916, 000914834.Organization: Health Canada
February 2021
Req # A-2020-001140
Adverse Drug Reaction (ADR) for RANITIDINE HYDROCHLORIDE. Report number: 000673364.Organization: Health Canada
February 2021
Req # A-2020-001153
Adverse Reaction Reports (AERs) for HYDROXYCHLOROQUINE SULFATE. Report numbers: E2B_03061164, E2B_03061214, E2B_03064558, E2B_03067077, E2B_03154905, E2B_03157311, E2B_03123930.Organization: Health Canada
February 2021
Req # A-2020-001174
Adverse Reaction Reports (AERs). Report numbers: E2B_02396410, E2B_02396651, E2B_02396724, E2B_02397078, E2B_02397199, E2B_02397202, E2B_02397228, E2B_02397798, E2B_02398866, E2B_02399023, E2B_02399064, E2B_02399428, E2B_02399708, E2B_02399709,…Organization: Health Canada
February 2021
Req # A-2020-001504
Adverse Drug Reaction (ADR) for Riva-Rosuvastatin. Report number: 000920995. ADR for Zevtera. Report number: 000920266.Organization: Health Canada
February 2021
Req # A-2020-001507
Adverse Drug Reaction (ADR). Report number: 000909105.Organization: Health Canada
February 2021
Req # A-2020-001182
Adverse Reaction Reports (AERs). Report numbers: E2B_02417794, E2B_02417839, E2B_02418123, E2B 02419266, E2B_02419267, E2B_02420129, E2B_02420380, E2B_02420387, E2B 02420403, E2B_02420408, E2B_02420409, E2B_02420413, E2B_02420468, E2B_02421443,…Organization: Health Canada
February 2021
Req # A-2020-001230
Adverse Reaction Reports (AERs). Report numbers: E2B_02682195, E2B_02680873, E2B_02611042.Organization: Health Canada
February 2021